Study on Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Meal ingestion releases gut hormones which stimulate insulin secretion. A most important gut hormone is the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly degraded and inactivated after its release by the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 therefore increases the concentration of active GLP-1 after meal ingestion, which augments insulin secretion. How this process is regulated after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Type 2 Diabetes |
Drug: Sitagliptin Drug: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Study of the Effect of Sitagliptin on the Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers |
- Glucagon-like Peptide-1 Secretion After Meal Ingestion [ Time Frame: 300 min ] [ Designated as safety issue: No ]Plasma GLP-1 levels will be measured during 300 min after meal ingestion for estimation of GLP-1 secretion
- Insulin Secretion After Ingestion of Meal [ Time Frame: 300 min ] [ Designated as safety issue: No ]Plasma insulin levels will be measured during 300 min after meal ingestion to estimation of insulin secretion
| Enrollment: | 12 |
| Study Start Date: | August 2009 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
A placebo tablet is given before ingestion of macronutrients
|
Drug: placebo
A placebo tablet is given before ingestion of macronutrients
|
|
Active Comparator: Sitagliptin
Sitagliptin is given before ingestion of macronutrients
|
Drug: Sitagliptin
100 mg sitagliptin before ingestion of macronutrient
Other Name: Januvia
|
Eligibility| Ages Eligible for Study: | 20 Years to 30 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy men
- Age 20-30 years
- BMI 20-30 kg/m2
Exclusion Criteria:
- Any disease
- Any medication
Contacts and Locations
More Information
Publications:
| Responsible Party: | Bo Ahren, Professor, Lund University |
| ClinicalTrials.gov Identifier: | NCT00885638 History of Changes |
| Other Study ID Numbers: | Lund University Diabetes 001 |
| Study First Received: | April 21, 2009 |
| Results First Received: | September 21, 2012 |
| Last Updated: | December 7, 2012 |
| Health Authority: | Sweden: Medical Products Agency |
Keywords provided by Lund University:
|
GLP-1 Insulin secretion Macronutrients |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Sitagliptin Dipeptidyl-Peptidase IV Inhibitors |
Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013